FOLFOX is a combination chemotherapy regimen that uses three drugs together: 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. The name is shorthand for those components. It’s one of the most widely used treatments for colorectal cancer, given as a series of infusions every two weeks over roughly six months.
What FOLFOX Treats
FOLFOX is FDA-approved for two main situations. The first is Stage III colon cancer after surgery to remove the tumor, where it serves as “adjuvant” therapy, meaning it targets any cancer cells that may remain in the body after the operation. The second is advanced colorectal cancer that has spread beyond the colon or rectum. It’s also sometimes used off-label for other gastrointestinal cancers, including stomach cancer.
How the Three Drugs Work Together
Each drug in the FOLFOX combination plays a distinct role, and together they’re more effective than any single one alone.
5-FU is the primary cancer-killing agent. It works by interfering with an enzyme that cancer cells need to copy their DNA and divide. Without that enzyme functioning properly, the cells can’t reproduce and eventually die. Leucovorin isn’t a chemotherapy drug itself. It’s a form of folate that locks 5-FU more tightly onto that enzyme, making the 5-FU significantly more potent. Think of leucovorin as an amplifier for the main drug.
Oxaliplatin is a platinum-based drug that attacks cancer from a different angle. It binds directly to DNA strands inside cells, creating physical damage that blocks the cell’s ability to replicate. Oxaliplatin also appears to reduce the body’s ability to break down 5-FU, which means more of the active drug stays in circulation longer. This interaction between the two drugs helps explain why the combination produces results that are better than what you’d expect from simply adding their individual effects together.
What a Treatment Cycle Looks Like
A standard course of FOLFOX runs about six months, with treatments given every two weeks for a total of 12 cycles. Each cycle spans roughly three days, though you won’t be in the clinic for all of that time.
On day one, you’ll go to the infusion center where leucovorin and oxaliplatin are given intravenously over a couple of hours. At the same time, a portion of the 5-FU is administered as a quick injection. Then a portable pump is connected to deliver the remaining 5-FU slowly over the next 46 to 48 hours. You go home wearing this pump, which is small enough to carry in a pouch or fanny pack. Two days later, you return to the clinic to have the pump disconnected. After that, you have about 12 days off before the next cycle begins.
Most people have a chemo port implanted before starting FOLFOX. This is a small device placed under the skin of the chest that connects to a large vein. The port gives the clinical team reliable access for every infusion and blood draw without repeatedly searching for veins in your arm. It also makes the process safer, since chemotherapy drugs like oxaliplatin and 5-FU can damage smaller veins or leak into surrounding tissue. The port is placed in a minor surgical procedure, usually a week or two before treatment starts.
Common Side Effects
Nausea and vomiting are among the most frequent side effects. In clinical data, about 74% of patients experience some degree of nausea, and vomiting affects a similar proportion, with around 30% experiencing severe episodes. Your oncology team will prescribe anti-nausea medications to manage this, and finding the right combination sometimes takes a cycle or two.
Diarrhea is relatively uncommon with FOLFOX compared to other regimens, affecting fewer than 9% of treatment cycles. Constipation is more likely, showing up in about 26% of cycles. Mouth sores occur in roughly 17% of patients but tend to be mild.
Severe drops in white blood cell counts, which raise the risk of infection, happen in about 8% of FOLFOX patients. This is notably lower than some alternative regimens, but your blood counts will still be checked before each cycle to make sure your body has recovered enough to proceed.
Nerve Damage and Cold Sensitivity
The side effect that distinguishes FOLFOX from many other regimens is peripheral neuropathy caused by oxaliplatin. It comes in two forms, and nearly all patients experience at least one of them.
The acute form hits about 50% of patients, often during or within hours of the infusion. It causes tingling, numbness, or strange sensations in the hands, feet, and around the mouth. The most distinctive symptom is extreme sensitivity to cold. Cold air, cold drinks, or even reaching into the refrigerator can trigger sharp pain, tingling in the throat, or a sensation of tightness in the jaw. Over 70% of patients with acute neuropathy report painful sensations in the throat triggered by cold, and a similar percentage experience numbness or tingling around the lips. These symptoms are temporary, typically fading within days of each infusion.
The chronic form develops in about 41% of patients and is cumulative, meaning it builds over successive treatment cycles. It shows up as persistent tingling, numbness, or pain in the fingers and toes that doesn’t go away between cycles. Unlike the acute form, chronic neuropathy isn’t triggered by cold. It’s caused by gradual damage to the nerves, and its severity depends on the total amount of oxaliplatin received over time. For some patients, it resolves within months of finishing treatment. For others, it can linger for a year or longer.
Practical adjustments during treatment include wearing gloves before touching anything cold, drinking room-temperature or warm beverages, and avoiding cold weather exposure when possible. Some oncologists will reduce the oxaliplatin dose or stop it entirely if neuropathy becomes severe, sometimes continuing with just 5-FU and leucovorin for the remaining cycles.
What to Expect Over Six Months
The first few cycles are often the most manageable. Side effects tend to be milder early on and accumulate as treatment progresses. Fatigue typically worsens with each cycle, and neuropathy becomes more noticeable in the later months. Many people are able to work or maintain a modified version of their normal routine during FOLFOX, particularly during the “off” week between cycles, though energy levels vary widely from person to person.
Recent clinical research has explored whether some patients can safely shorten their treatment from six months to three months. This is an active area of discussion between oncologists and patients, particularly for Stage III colon cancer where the disease is considered lower risk. The tradeoff is potentially less neuropathy and fewer cumulative side effects in exchange for a small possible reduction in effectiveness. Your oncologist can help weigh these factors based on your specific cancer stage and risk profile.